Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.

Pariente A, Daveluy A, Laribière-Bénard A, Miremont-Salame G, Begaud B, Moore N.

Drug Saf. 2009;32(5):441-7. doi: 10.2165/00002018-200932050-00007.

PMID:
19419238
2.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

3.

Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs).

Hedenmalm K, Sundström A, Spigset O.

Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):719-25.

PMID:
16783834
5.

Adverse event reporting with selective serotonin-reuptake inhibitors.

Hartnell NR, Wilson JP, Patel NC, Crismon ML.

Ann Pharmacother. 2003 Oct;37(10):1387-91.

PMID:
14519041
6.

Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.

Kim S, Park K, Kim MS, Yang BR, Choi HJ, Park BJ.

Psychiatry Res. 2017 Oct;256:237-242. doi: 10.1016/j.psychres.2017.06.038. Epub 2017 Jun 13.

PMID:
28646789
7.

A comparative study of QT prolongation with serotonin reuptake inhibitors.

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL.

Psychopharmacology (Berl). 2017 Oct;234(20):3075-3081. doi: 10.1007/s00213-017-4685-7. Epub 2017 Aug 3.

PMID:
28770276
8.

How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.

Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ; Yellow Card Study Collaboration.

Drug Saf. 2013 Mar;36(3):199-206. doi: 10.1007/s40264-013-0021-2.

PMID:
23444232
9.
10.

Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

Tomlin A, Reith D, Dovey S, Tilyard M.

Drug Saf. 2012 Sep 1;35(9):733-43. doi: 10.2165/11631970-000000000-00000.

PMID:
22861670
11.

Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Edwards JG, Anderson I.

Drugs. 1999 Apr;57(4):507-33. Erratum in: Drugs 1999 Dec;58(6):1207-9.

PMID:
10235690
12.

Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins.

van Hunsel F, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K.

Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):26-32. doi: 10.1002/pds.1865.

PMID:
19953500
13.

Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.

Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, Motola D, Salvo F, Rivolta AL, Blandizzi C, Mugelli A, Del Tacca M.

Drug Saf. 2008;31(12):1115-23. doi: 10.2165/0002018-200831120-00007.

PMID:
19026028
14.
15.

A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.

Hou Y, Ye X, Wu G, Cheng G, Du X, He J.

Expert Opin Drug Saf. 2014 Jul;13(7):853-7. doi: 10.1517/14740338.2014.915938. Epub 2014 Jun 11.

PMID:
24918197
17.

Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

Aagaard L, Hansen EH.

BMC Clin Pharmacol. 2009 Mar 3;9:4. doi: 10.1186/1472-6904-9-4. Review.

18.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

19.

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.

Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L.

Cochrane Database Syst Rev. 2015 May 1;(5):CD011681. doi: 10.1002/14651858.CD011681. Review.

PMID:
25931277
20.

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors?

Dalfen AK, Stewart DE.

Can J Psychiatry. 2001 Apr;46(3):258-63.

PMID:
11320680

Supplemental Content

Support Center